Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case
Rev. méd. Chile; 148 (9), 2020
ABSTRACT Myelodysplastic syndrome with deletion of chromosome 5q (5q-syndrome) has a favorable prognosis and a low risk of transformation to acute myeloid leukemia, when treated with lenalidomide. Azacitidine leads to complete remission even as second-line therapy and in patients with clonal evolution. W...
Anemia Macrocítica, Inhibidores de la Angiogénesis, Deleción Cromosómica, Síndromes Mielodisplásicos, Talidomida, Anemia Macrocítica/tratamiento farmacológico, Anemia Macrocítica/genética, Inhibidores de la Angiogénesis/uso terapéutico, Cromosomas Humanos Par 5/genética, Lenalidomida, Síndromes Mielodisplásicos/tratamiento farmacológico, Síndromes Mielodisplásicos/genética, Talidomida/uso terapéutico, Resultado del Tratamiento